RemeGen Co., Ltd. (HKG:9995)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
85.30
+8.40 (10.92%)
Mar 6, 2026, 4:08 PM HKT
402.95%
Market Cap 59.85B
Revenue (ttm) 3.62B
Net Income (ttm) 788.45M
Shares Out 556.51M
EPS (ttm) 1.44
PE Ratio 59.42
Forward PE 39.95
Dividend n/a
Ex-Dividend Date n/a
Volume 9,891,100
Average Volume 2,969,229
Open 76.90
Previous Close 76.90
Day's Range 75.30 - 85.75
52-Week Range 15.50 - 126.60
Beta 0.72
RSI 56.44
Earnings Date Mar 28, 2026

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial gro... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 3,070
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9995
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.